SURROZEN, INC./DE

Profile

Company Names

SURROZEN, INC./DE

Addresses

171 OYSTER POINT BLVD, SUITE 400, SOUTH SAN FRANCISCO, CA 94080

Phone Numbers

650-475-2820

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2021

State Incorporated:

DELAWARE

Total Amount Raised:

$269,418,239.00

Number of Funding Rounds:

2
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
2
2025-03-26 
$76,402,277.00 
$174,999,955.00 
$98,597,678.00 
Equity 
1
2024-04-04 
$193,015,962.00 
$193,015,962.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
ANNA 
 
BERKENBLIT, M.D. 
DIRECTOR
SURROZEN, INC./DE
ERIC 
 
BJERKHOLT 
DIRECTOR
CALCIMEDICA, INC.   |  SURROZEN, INC./DE   |  MIRUM PHARMACEUTICALS, INC.
CHRISTOPHER 
 
CHAI 
DIRECTOR
SURROZEN, INC./DE
MARY 
 
HAAK-FRENDSCHO, PH.D. 
DIRECTOR
SURROZEN, INC./DE
TIM 
 
KUTZKEY, PH.D. 
DIRECTOR
COLUMN GROUP II, LP   |  SURROZEN, INC./DE
YANG 
 
LI, PH.D. 
EXECUTIVE OFFICER
SURROZEN, INC./DE
SHAO-LEE 
 
LIN, M.D., PH.D. 
DIRECTOR
SURROZEN, INC./DE
CRAIG 
 
PARKER 
EXECUTIVE OFFICER, DIRECTOR
VTV THERAPEUTICS INC.   |  SURROZEN, INC.   |  SURROZEN, INC./DE   |  SAFEIDENTITY HOLDINGS, INC.   |  NAVIDENCE, INC.
MACE 
 
ROTHENBERG, M.D. 
DIRECTOR
SURROZEN, INC./DE
CHARLES 
 
WILLIAMS 
EXECUTIVE OFFICER
3270 SOUTH GRANT LLC   |  SURROZEN, INC./DE
DAVID 
J. 
WOODHOUSE, PH.D. 
DIRECTOR
SURROZEN, INC./DE
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2025-04-08
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2025-03-26 
2024-04-19
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2024-04-04 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
GUGGENHEIM SECURITIES, LLC
40638